Abstract: The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD50 Units) than available formulations of botulinum toxins. These improved formulations enable physicians to treat a wide variety of pathological conditions with a lower toxin load that reduces the risk of inducing an immune response against the toxin and its associated proteins that may ultimately lead to the development of toxin resistance. These benefits are particularly important in the treatment of conditions that require high-dose or chronic administration of botulinum toxin. Additionally, the decreased in LD50 Unit doses of inventive formulations allows for controlled administration limits diffusion. The present invention also provides methods of treating neuromuscular diseases and pain, using low-dose botulinum toxin.

Abstract: The present invention relates in a first embodiment to a polymer film comprising a propylene random copolymer with a total comonomer content of 4.5 to 12 mol % wherein the sealing initiation temperature SIT of the film is Tm?30° C. or less, preferably Tm?33° C. or less, in a second embodiment to a polymer film comprising a propylene random copolymer with a total comonomer content of 4.5 to 12 mol % wherein the film is having a relative reduction of the static friction value (inside-inside) from one to four days of 35% or more, preferably 40% or more, in a third embodiment to a polymer film comprising a propylene random copolymer with a total comonomer content of 4.5 to 12 mol % wherein the distribution of the comonomer in the random copolymer determined according to TREF method is multimodal, preferably bimodal, in a fourth embodiment to a polymer film comprising a propylene random copolymer with a total comonomer content of 4.5 to 12 mol %, wherein the copolymer is having an elution interval of 50° C.

Abstract: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention further relates to compositions, methods and kits comprising artificial LDL particles for targeting drugs to and across the BBB for the prevention and treatment of brain diseases.

Abstract: A method of diagnosing Alzheimer's disease in a patient comprises determining whether the phosphorylation level of an indicator protein in cells of the patient after stimulus with an activator compound is abnormally elevated as compared to a basal phosphorylation level, the indicator protein being e.g. Erk1/2 and the activator compound being e.g. bradykinin.

Abstract: Botulinum toxin has been shown to be useful for the treatment of pain when administered for cervical dystonia. Given efficacy for pain relief in regional dystonia, further expanded applications have included myofascial pain, muscle tension headaches, and other forms of headache syndromes. The application in headache practice has expanded to migraine as well as certain secondary headache syndromes. Although multiple case reports involving the use of botulinum toxin have shown promise in its utility for the treatment of primary pain syndromes, to date, controlled trials have failed to consistently and more definitively prove utility. Described herein is a method for selection of patients with headache syndromes more likely to respond to botulinum administration.

Abstract: The lowest trade price for a security within a predetermined period of time is determined, and a momentum liquidity replenishment price is determined by adding the greater of a predetermined price or a predetermined percentage of the last trade price to the lowest trade price for the security for the security within the predetermined period of time. In a similar fashion, another momentum liquidity replenishment price is determined from the highest trading price of the security within predetermined period of time.

Abstract: Use of micronized zinc compounds in wood preservation treatments containing micronized copper compounds significantly increases the efficacy of the treatment with respect to that of the copper compounds alone. Micronized copper compounds used at a retention in the range of from 0.005 to 1 pounds per cubic foot (pcf) expressed as CuO equivalent, and zinc compounds are used at a retention in the range of from 0.005 to 1 pcf expressed as ZnO equivalent, the increase in wood preservation efficacy over similar retentions of copper compounds alone can be seen in as little as 24 months.

Abstract: We disclose and claim a method for custom fitting an article to a human being or animal comprising, selecting on the basis of body information about said human being or animal a subset of entries from a database populated with entries, wherein said entries comprise data from which said article is designed. We also disclose and claim a method for custom fitting an article to a human being or animal comprising, obtaining body information about said human being or animal, populating a database with entries comprising data about other individual human beings or animals selected from the group consisting of body dimensions and body information, selecting a subset of entries from said database on the basis of said body information about said human being or animal, and designing said article on the basis of said subset of entries.

Abstract: A drive assembly, particularly for driving arms around a compartment in a waste material digester, comprises a rotatable hub having an inner drive plate and a ratchet plate secured thereto for rotation therewith. Positionally opposed, parallel piston and cylinder drive reciprocatably drive an outer drive plate, drive arms pivotally carried on the outer drive plate engaging with drive pins on the inner drive plate to drive the hub in one direction. Movement of the hub in the opposite direction is prevented by latches engaging with respective shoulders of the ratchet plate when the outer drive plate moves in said opposite direction.

Abstract: The present invention is for composition containing extract of Northern White Kidney Bean (Phaseolus vulgaris), extract of Red Kidney Bean (Phaseolus vulgaris) and extract of Green Tea (Camellia Sinensis ). This invention as a supplemental compound, aids in weight reduction both in overweight and obese individuals. This invention helps normal weight subjects in improving their quality of life by maintaining their normal weight. Included is also folic acid, (B6) and B12 and the whole supplement is bound by a vegetable matrix. The present invention is directed to methods for inducing weight loss by inhibit the absorption of dietary lipids and starch, increase the metabolic rate and decrease the amino acid homocysteine in the blood, an amino acid known to cause risk of heart disease, by administering a composition of the invention. Due to the content of the green tea extract this invention is also meant to reduce and prevent occurrence of gastrointestinal cancer and cancer of the prostate.

Abstract: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention further relates to compositions, methods and kits comprising artificial LDL particles for targeting drugs to and across the BBB for the prevention and treatment of brain diseases.

Abstract: A plurality of limit orders are received at the same price and the limit orders are aggregated as a single aggregate. A plurality of broker interests are received at the same price. Equal parity is assigned to the single aggregate and each of the plurality of broker interests.

Abstract: A display device of the present invention has a drain driver mounted to a display substrate and having a gate driver and a controller therein, and also has a power source mounted to a flexible printed board and supplying a power voltage to the gate driver. The wiring of a common control signal outputted from the controller and commonly used in control of the gate driver and the power source is formed on the display substrate so that the number of pads for connecting the display substrate and the flexible printed board is reduced. Thus, the construction of the flexible printed board is simplified, and the entire display device can be made compact.

Abstract: In certain aspects, the invention features a system and method for caching results, including receiving a job for computation by a distributed computing system having one or more node computing devices in communication with a cache, processing, on one of the node computing devices, the job to create an intermediate result for storage in the cache, wherein the intermediate result includes data wherein a time required to obtain the data by computation or retrieval from a data storage external to the distributed computer system is at least marginally greater than that of retrieving the intermediate result from the cache. In accordance with such aspects, the system and method further includes storing the intermediate result in the cache, and accessing the cache by presenting a lookup function to the cache, wherein the lookup function includes a key and a compute function configured to produce the intermediate result.

Abstract: A method for the preparation of a composite product, as well as the composite product. The composite product comprises at least two layers. At least one of the layers is of wood or another cellulose-containing material. The process comprises differentially treating the layers prior to, during, or after the lamination of the layers into a composite product.

Abstract: Pharmaceutical application of a chemodenervating agent, particularly botulinum toxin, reduces inflammatory response and serves as an anti-inflammatory agent without systemic side effects and with long duration action, on the order of 12-24 weeks. In one embodiment, the effective dosage for allergy provoked inflammation reduction is an order of magnitude less than dosages associated with treatment of regional movement diseases, since the agent works to reduce inflammation by reducing histamine and other preformed mediator releases associated with mast cell degranulation.

Abstract: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention further relates to compositions, methods and kits comprising artificial LDL particles for targeting drugs to and across the BBB for the prevention and treatment of brain diseases.

Abstract: The present invention ensures the hermetic bonding of a support body which is interposed between a face substrate and a back substrate and is formed of a plurality of members thus easily realizing the large-sizing of a screen of a display image and, at the same time, enhancing a hermetic property holding function of the image display device. A support body is interposed between a face substrate and a back substrate while surrounding a display region and hermetically seals both substrates using a sealing material. The support body is formed by hermetically bonding a plurality of support body members each other using a bonding material which has a softening point higher than a softening point of the sealing material.

Abstract: This invention relates to a composition of botulinum based pharmaceuticals used for therapeutic and cosmetic treatment. This invention offers an improvement on the prior art by eliminating the potential of blood-borne contamination with botulinum based pharmaceuticals. Recombinant serum albumin is taught for use in the place of human serum albumin as a stabilizing or enhancing agent.

Abstract: In an exposure step for forming a phosphor screen of a color cathode ray tube, correction lenses which are arranged between a light source and a panel are used in a state that a common correction lens which is used in common for three colors and three kinds of monochroic correction lenses are combined. The present invention can, in a flat-face-type color cathode ray tube, prevent the generation of the mislanding attributed to the difference in a wall thickness between a center portion and a peripheral portion of a panel thus improving the color purity.